KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Long-Term Deferred Tax (2022 - 2024)

Historic Long-Term Deferred Tax for Acadia Pharmaceuticals (ACAD) over the last 4 years, with Q4 2024 value amounting to $8.7 million.

  • Acadia Pharmaceuticals' Long-Term Deferred Tax rose 2794.12% to $8.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.7 million, marking a year-over-year increase of 2794.12%. This contributed to the annual value of $8.7 million for FY2024, which is 2794.12% up from last year.
  • As of Q4 2024, Acadia Pharmaceuticals' Long-Term Deferred Tax stood at $8.7 million, which was up 2794.12% from $6.8 million recorded in Q4 2023.
  • Acadia Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $8.7 million for Q4 2024, and its period low was $1.2 million during Q4 2022.
  • For the 3-year period, Acadia Pharmaceuticals' Long-Term Deferred Tax averaged around $5.6 million, with its median value being $6.8 million (2023).
  • Per our database at Business Quant, Acadia Pharmaceuticals' Long-Term Deferred Tax surged by 46666.67% in 2023 and then skyrocketed by 2794.12% in 2024.
  • Over the past 3 years, Acadia Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $1.2 million in 2022, then surged by 466.67% to $6.8 million in 2023, then increased by 27.94% to $8.7 million in 2024.
  • Its last three reported values are $8.7 million in Q4 2024, $6.8 million for Q4 2023, and $1.2 million during Q4 2022.